Nektar Therapeutics (NASDAQ: NKTR) kicked off on Monday, up 6.36% from the previous trading day, before settling in for the closing price of $1.10. Over the past 52 weeks, NKTR has traded in a range of $0.48-$1.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -2.93%. While this was happening, its average annual earnings per share was recorded 51.45%. With a float of $177.74 million, this company’s outstanding shares have now reached $184.46 million.
Considering the fact that the conglomerate employs 137 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 67.8%, operating margin of -145.96%, and the pretax margin is -180.71%.
Nektar Therapeutics (NKTR) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nektar Therapeutics is 3.64%, while institutional ownership is 74.35%. The most recent insider transaction that took place on Dec 23 ’24, was worth 30,062. In this transaction Chief Legal Officer of this company sold 33,402 shares at a rate of $0.90, taking the stock ownership to the 351,892 shares. Before that another transaction happened on Dec 24 ’24, when Company’s Chief Legal Officer sold 16,560 for $0.89, making the entire transaction worth $14,738. This insider now owns 335,332 shares in total.
Nektar Therapeutics (NKTR) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 51.45% per share during the next fiscal year.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Take a look at Nektar Therapeutics’s (NKTR) current performance indicators. Last quarter, stock had a quick ratio of 4.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.74 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Compared to the last year’s volume of 2.12 million, its volume of 1.64 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 75.22%. Additionally, its Average True Range was 0.08.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 48.38%, which indicates a significant decrease from 85.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.68% in the past 14 days, which was higher than the 69.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1122, while its 200-day Moving Average is $1.2686. Nevertheless, the first resistance level for the watch stands at $1.2167 in the near term. At $1.2633, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3067. If the price goes on to break the first support level at $1.1267, it is likely to go to the next support level at $1.0833. Should the price break the second support level, the third support level stands at $1.0367.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
The company with the Market Capitalisation of 247.03 million has total of 184,458K Shares Outstanding. Its annual sales at the moment are 90,120 K in contrast with the sum of -276,060 K annual income. Company’s last quarter sales were recorded 24,120 K and last quarter income was -37,060 K.
